Immunotherapy of tumors with human telomerase reverse transcriptase immortalized human umbilical vein endothelial cells

International Journal of Oncology

Volumn 47, Issue 5, 2015, Pages 1901-1911

  Mu, Xiyan ^a,b   Sang, Yaxiong ^b   Fang, Chunju ^b   Shao, Bin ^b   Yang, Lu ^a   Yao, Kui ^a   Zhao, Xitong ^a   Gou, Jinhai ^a   Wei, Yuquan ^b   Yi, Tao ^a   Wu, Yang ^b   Zhao, Xia ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

hTERT; Human umbilical endothelial cells; Immortalization; Immunotherapy; Microenvironment

Indexed keywords

ALPHA5 INTEGRIN; CD31 ANTIGEN; NEUTRALIZING ANTIBODY; TELOMERASE REVERSE TRANSCRIPTASE; VASCULOTROPIN RECEPTOR 2; CANCER VACCINE; TELOMERASE; TERT PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL IMMORTALIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; SUPPRESSOR CELL; TELOMERE; TUMOR IMMUNITY; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; TELOMERE;

EID: 84942944999     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3175     Document Type: Article

References (37)

1. Okaji Y, Tsuno NH, Saito S, Yoneyama S, Tanaka M, Nagawa H and Takahashi K: Vaccines targeting tumour angiogenesis-a novel strategy for cancer immunotherapy. Eur J Surg Oncol 32: 363-370, 2006.
2. Boehm T, Folkman J, Browder T and O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.
3. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specifc, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543, 1993.
4. Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, Niu T, Liu F, Jiang Y, Hu B, et al: Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102: 1815-1823, 2003.
5. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, et al: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6: 1160-1166, 2000.
6. Chen XY, Zhang W, Zhang W, Wu S, Bi F, Su YJ, Tan XY, Liu JN and Zhang J: Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin Cancer Res 12: 5834-5840, 2006.
7. Okaji Y, Tsuno NH, Tanaka M, Yoneyama S, Matsuhashi M, Kitayama J, Saito S, Nagura Y, Tsuchiya T, Yamada J, et al: Pilot study of anti-angiogenic vaccine using fxed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer 44: 383-390, 2008.
8. Chang MW, Grillari J, Mayrhofer C, Fortschegger K, Allmaier G, Marzban G, Katinger H and Voglauer R: Comparison of early passage, senescent and hTERT immortalized endothelial cells. Exp Cell Res 309: 121-136, 2005.
9. Böcker W, Yin Z, Drosse I, Haasters F, Rossmann O, Wierer M, Popov C, Locher M, Mutschler W, Docheva D, et al: Introducing a single-cell-derived human mesenchymal stem cell line expressing hTERT after lentiviral gene transfer. J Cell Mol Med 12: 1347-1359, 2008.
10. Freedman DA and Folkman J: Maintenance of G1 checkpoint controls in telomerase-immortalized endothelial cells. Cell Cycle 3: 811-816, 2004.
11. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S and Wright WE: Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352, 1998.
12. Zhu J, Wang H, Bishop JM and Blackburn EH: Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci USA 96: 3723-3728, 1999.
13. Anno K, Hayashi A, Takahashi T, Mitsui Y, Ide T and Tahara H: Telomerase activation induces elongation of the telomeric single-stranded overhang, but does not prevent chromosome aberrations in human vascular endothelial cells. Biochem Biophys Res Commun 353: 926-932, 2007.
14. Young AT, Lakey JR, Murray AG, Mullen JC and Moore RB: In vitro senescence occurring in normal human endothelial cells can be rescued by ectopic telomerase activity. Transplant Proc 35: 2483-2485, 2003.
15. von Zglinicki T: Oxidative stress shortens telomeres. Trends Biochem Sci 27: 339-344, 2002.
16. Yang J, Chang E, Cherry AM, Bangs CD, Oei Y, Bodnar A, Bronstein A, Chiu CP and Herron GS: Human endothelial cell life extension by telomerase expression. J Biol Chem 274: 26141-26148, 1999.
17. Yang J, Nagavarapu U, Relloma K, Sjaastad MD, Moss WC, Passaniti A and Herron GS: Telomerized human microvascula-ture is functional in vivo. Nat Biotechnol 19: 219-224, 2001.
18. Li Y, Shen G, Nie W, Li Z, Sang Y, Zhang B and Wei Y: Irradiated tumor cells of lipopolysaccharide stimulation elicit an enhanced anti-tumor immunity. J Cancer Res Clin Oncol 140: 1815-1823, 2014.
19. Zhao Z, Yao Y, Ding Z, Chen X, Xie K, Luo Y, Zhang J, Chen X, Wu X, Xu J, et al: Antitumour immunity mediated by mannan-modifed adenovirus vectors expressing VE-cadherin. Vaccine 29: 4218-4224, 2011.
20. Zhou X, Li J, Wang Z, Chen Z, Qiu J, Zhang Y, Wang W, Ma Y, Huang N, Cui K, et al: Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia 15: 544-553, 2013.
21. Gupta S, Marcel N, Sarin A and Shivashankar GV: Role of actin dependent nuclear deformation in regulating early gene expression. PLoS One 7: e53031, 2012.
22. Zhang C, Shan J, Lu J, Huang Y, Feng L, Long D, Li S, Li Q and Li Y: Combination of rapamycin and IL-2 do not affect antigen presentation ability of rat B cell and could promote Tregs proliferation and inhibitory activity. Cell Immunol 264: 180-185, 2010.
23. Skabytska Y, Wölbing F, Günther C, Köberle M, Kaesler S, Chen KM, Guenova E, Demircioglu D, Kempf WE, Volz T, et al: Cutaneous innate immune sensing of Toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity 41: 762-775, 2014.
24. Li Y, Zhao YJ, Zou QY, Zhang K, Wu YM, Zhou C, Wang K and Zheng J: Preeclampsia does not alter vascular growth and expression of CD31 and vascular endothelial cadherin in human placentas. J Histochem Cytochem 63: 22-31, 2015.
25. Bürgler S, Gimeno A, Parente-Ribes A, Wang D, Os A, Devereux S, Jebsen P, Bogen B, Tjønnfjord GE and Munthe LA: Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism. J Immunol 194: 827-835, 2015.
26. Lohoff M, Giaisi M, Köhler R, Casper B, Krammer PH and Li-Weber M: Early growth response protein-1 (Egr-1) is preferentially expressed in T helper type 2 (Th2) cells and is involved in acute transcription of the Th2 cytokine interleukin-4. J Biol Chem 285: 1643-1652, 2010.
27. Mulligan JK and Young MR: Tumors induce the formation of suppressor endothelial cells in vivo. Cancer Immunol Immunother 59: 267-277, 2010.
28. Blank S, Deck C, Dreikhausen L, Weichert W, Giese N, Falk C, Schmidt T and Ott K: Angiogenic and growth factors in gastric cancer. J Surg Res 194: 420-429, 2015.
29. +) regulatory T cells. Biol Blood Marrow Transplant 15: 1239-1243, 2009.
30. Fernández A, Oliver L, Alvarez R, Fernández LE, Lee KP and Mesa C: Adjuvants and myeloid-derived suppressor cells: Enemies or allies in therapeutic cancer vaccination. Hum Vaccin Immunother 10: 3251-3260, 2014.
31. Xing X, Gu X, Ma T and Ye H: Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer. Tumour Biol 36: 1773-1780, 2015.
32. Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, Yazawa K, Asakage M, Hori N, Watanabe T, et al: Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci 95: 85-90, 2004.
33. Toomer KH and Chen Z: Autoimmunity as a double agent in tumor killing and cancer promotion. Front Immunol 5: 116, 2014.
34. Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM and Melief CJ: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186: 695-704, 1997.
35. Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G and Sun Y: New horizons in tumor microenvironment biology: Challenges and opportunities. BMC Med 13: 45, 2015.
36. Koh BI and Kang Y: The pro-metastatic role of bone marrow-derived cells: A focus on MSCs and regulatory T cells. EMBO Rep 13: 412-422, 2012.
37. Pacini S: Deterministic and stochastic approaches in the clinical application of mesenchymal stromal cells (MSCs). Front Cell Dev Biol 2: 50, 2014.